Initial Management of Symptomatic Bradycardia

Assessment and Initial Steps

The American Heart Association recommends evaluating the appropriateness of heart rate for clinical condition, typically less than 50 beats per minute when symptomatic, to determine the need for intervention 1
The American College of Cardiology suggests identifying signs and symptoms of poor perfusion, such as altered mental status, ischemic chest discomfort, acute heart failure, hypotension, or shock, to determine if they are caused by bradycardia 1, 2
Maintaining a patent airway and assisting breathing as necessary is crucial in the initial management of symptomatic bradycardia, according to the American Heart Association 3, 1
Providing supplementary oxygen if hypoxemic is essential, as hypoxemia is a common cause of bradycardia, as stated by the American College of Cardiology 1, 4
Attaching a cardiac monitor to identify rhythm, monitor blood pressure, and measure oxygen saturation is a critical step in the assessment of symptomatic bradycardia, recommended by the American Heart Association 1
Establishing IV access is necessary for the administration of medications, as suggested by the American College of Cardiology 3, 1
Obtaining a 12-lead ECG if available is recommended, but should not delay therapy, according to the American Heart Association 1, 4

The American College of Cardiology states that medications, such as beta blockers, calcium channel blockers, digoxin, and antiarrhythmic drugs, are frequent causes of symptomatic bradycardia 5, 6
Electrolyte abnormalities, such as hyperkalemia and hypokalemia, can contribute to symptomatic bradycardia, as noted by the American Heart Association 6
Hypothyroidism is a potential reversible cause of symptomatic bradycardia, according to the American College of Cardiology 5, 6
Acute myocardial ischemia or infarction can cause symptomatic bradycardia, as stated by the American Heart Association 6, 2
Increased intracranial pressure, hypothermia, infections, and sleep apnea are other potential reversible causes of symptomatic bradycardia, as suggested by the American College of Cardiology 5, 6

The American Heart Association recommends atropine as the first-line drug for acute symptomatic bradycardia, with a Class IIa, LOE B recommendation 7, 8, 2
The recommended atropine dose is 0.5 mg IV every 3-5 minutes to a maximum total dose of 3 mg, as stated by the American College of Cardiology 2
Atropine should be considered a temporizing measure while awaiting pacemaker placement if needed, according to the American Heart Association 2

The American College of Cardiology suggests that if bradycardia is unresponsive to atropine, IV infusion of β-adrenergic agonists, such as dopamine or epinephrine, can be effective, with a Class IIa, LOE B recommendation 7, 8
Dopamine infusion may be used particularly if bradycardia is associated with hypotension, with a Class IIb, LOE B recommendation, as stated by the American Heart Association 7, 8
Transcutaneous pacing is reasonable to initiate in unstable patients who don't respond to atropine, with a Class IIa, LOE B recommendation, according to the American College of Cardiology 7, 8, 2

The American Heart Association recommends considering expert consultation for complex cases, and preparing for transvenous pacing if temporary measures are ineffective 1, 2
Permanent pacing may be indicated for chronic symptomatic bradycardia, particularly if caused by necessary medications with no alternatives, as stated by the American College of Cardiology 9, 5

The American College of Cardiology indicates that permanent pacemaker is recommended for sinus node dysfunction with documented symptomatic bradycardia, which is a Class I indication for permanent pacing 10, 11
Permanent pacemaker evaluation is appropriate if bradycardia is documented and symptomatic, with correlation between symptoms and documented bradycardia being essential before proceeding to permanent pacing 10, 11

The American College of Cardiology recommends obtaining a 12-lead ECG to document rhythm, rate, and conduction abnormalities, but do not delay treatment in patients with symptomatic bradycardia 12

The American College of Cardiology suggests that cardiac causes, such as acute myocardial ischemia or infarction, especially inferior MI, should be considered and treated in patients with symptomatic bradycardia 12
The American College of Cardiology recommends screening for obstructive sleep apnea, particularly if bradycardia occurs during sleep, as a potential reversible cause of symptomatic bradycardia 13

The American College of Cardiology recommends atropine as the first-line drug for acute symptomatic bradycardia, with a dose of 0.5-1 mg IV bolus, repeated every 3-5 minutes to a maximum total dose of 3 mg 12, 13
The American College of Cardiology advises against using atropine in heart transplant patients without evidence of autonomic reinnervation, as it can cause paradoxical effects 12, 13

The American College of Cardiology recommends using IV beta-adrenergic agonists, such as dopamine, epinephrine, or isoproterenol, if bradycardia is unresponsive to atropine or atropine is contraindicated 12, 13
The American College of Cardiology suggests using glucagon 3-10 mg IV with infusion of 3-5 mg/h for beta-blocker or calcium channel blocker overdose 12

The American College of Cardiology recommends using 10% calcium chloride or 10% calcium gluconate for calcium channel blocker overdose 12

The American College of Cardiology recommends initiating transcutaneous pacing in unstable patients who do not respond to atropine 13

The American Heart Association recommends intervening immediately in patients with bradycardia who exhibit signs of hemodynamic instability, such as altered mental status, ischemic chest discomfort, acute heart failure, hypotension, or other signs of shock, with a Class IIa recommendation for atropine administration 14
The American College of Cardiology suggests that patients with high-grade AV block (Mobitz type II or greater) causing symptoms should receive permanent pacemaker implantation, with a Class I indication 15

The American Heart Association recommends atropine 0.5 mg IV every 3-5 minutes to a maximum of 3 mg total as first-line treatment for acute symptomatic bradycardia, with a Class IIa recommendation 14
Dopamine infusion is a reasonable second-line treatment for bradycardia, particularly in patients with hypotension, with a Class IIb recommendation 14

Transcutaneous pacing (TCP) is a reasonable intervention in unstable patients who do not respond to atropine, with a Class IIa recommendation 14
Transvenous pacing is indicated in patients who do not respond to drugs or TCP, or in unstable patients with high-degree AV block when IV access is unavailable, with a Class IIb recommendation 14

The American College of Cardiology suggests that patients with terminal illness who are not candidates for treatment should not receive intervention for bradycardia unless symptoms develop, with guidance from the Journal of the American College of Cardiology 16, 17

The American Heart Association advises against delaying treatment to obtain a 12-lead ECG in unstable patients, and against using verapamil for wide-complex tachycardias that may represent ventricular escape rhythms, with a recommendation from Circulation 14